Aura Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Aura Biosciences, Inc. (Nasdaq: AURA) filed this Current Report on Form 8-K on August 5, 2026, to disclose the results of a Special Meeting of Stockholders held on the same date. The record date for the meeting was June 12, 2026.
Key Financial Metrics
This filing is a corporate governance report regarding stockholder votes and does not contain financial performance data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
At the Special Meeting, 89,490,726 shares were represented, constituting a quorum out of 103,436,416 outstanding shares. Stockholders approved two proposals:
- Proposal 1: Approval of an amendment to the Tenth Amended and Restated Certificate of Incorporation to increase authorized common stock from 150,000,000 to 500,000,000 shares.
- Votes For: 62,993,701
- Votes Against: 26,496,186
- Abstentions: 839
- Proposal 2: Approval of Amendment No. 1 to the 2021 Stock Option and Incentive Plan.
- Votes For: 46,369,676
- Votes Against: 27,372,773
- Abstentions: 819
- Broker Non-Votes: 15,747,458
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It refers investors to the Definitive Proxy Statement on Schedule 14A filed on June 29, 2026, for detailed information regarding the proposals.
Key Facts for Investor Verification
- Verify the effective date of the Certificate of Incorporation amendment to confirm the new 500,000,000 share authorization is active.
- Review the specific terms of Amendment No. 1 to the 2021 Stock Option and Incentive Plan in the Schedule 14A filing to understand the impact on equity dilution.
- Note the significant number of broker non-votes (15.7 million) on Proposal 2, indicating a portion of shares held in street name did not receive voting instructions.